$1,318.00
This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Watchful waiting
8 Pharmacological treatment
8 Surgical treatment
10 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 Fexapotide for BPH (May 20, 2022)
23 KEY REGULATORY EVENTS
23 FDA Nixes Nymox NDA For Lack Of Long-Term Safety Data
23 Nymox Fexapotide Odyssey Reaches FDA
24 PROBABILITY OF SUCCESS
25 LICENSING AND ASSET ACQUISITION DEALS
25 Torrent Acquires Chronic Brands From Dr Reddy’s, Folds Up US Liquids Business
26 REVENUE OPPORTUNITY
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
32 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of BPH, 2021–30
17 Figure 2: Overview of pipeline drugs for BPH in the US
17 Figure 3: Pipeline drugs for BPH, by company
17 Figure 4: Pipeline drugs for BPH, by drug type
18 Figure 5: Pipeline drugs for BPH, by classification
24 Figure 6: Probability of success in the urology pipeline
28 Figure 7: Clinical trials in BPH
28 Figure 8: Top 10 drugs for clinical trials in BPH
29 Figure 9: Top 10 companies for clinical trials in BPH
29 Figure 10: Trial locations in BPH
30 Figure 11: BPH trials status
31 Figure 12: BPH trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of BPH, 2021–30
13 Table 2: Prevalence proportions of BPH, by age
15 Table 3: Marketed drugs for BPH
19 Table 4: Pipeline drugs for BPH in the US
21 Table 5: Fexapotide for BPH (May 20, 2022)
26 Table 6: Historical global sales, by drug ($m), 2017–21
27 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!